Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

67.38 -0.56 (-0.83%)
Streaming Delayed Price Updated: 1:41 PM EDT, Sep 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs
AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation 
Via Benzinga
AstraZeneca Unusual Options Activity For September 28
Via Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY 
Via Benzinga
Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs
U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria.  More than a million people worldwide succumb to infections caused... 
Via Benzinga
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories
Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate
The European Medicines Agency (EMA) is set to address concerns related to patients taking drugs such as Novo Nordisk A/S's (NYSE 
Via Benzinga
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder
IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder. 
Via Investor's Business Daily
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
Read the latest report on NanoViricides here 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Via Benzinga
Baidu To Rally Over 29%? Here Are 10 Other Analyst Forecasts For Monday
Goldman Sachs increased the price target for Constellation Brands, Inc. (NYSE: STZ) from $275 to $305. Goldman Sachs analyst Bonnie Herzog maintained a Buy rating. Constellation shares fell 0.8% to... 
Via Benzinga
3 Magnificent Growth Stocks to Buy Right Now
If you're looking for growth, these stocks could be just the ticket. 
Via The Motley Fool
AstraZeneca Surges To 50-Day Line After Breast Cancer Drug Tops Chemo
The companies are still testing to see if their drug has a benefit on overall survival. 
Via Investor's Business Daily
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:  
Via Benzinga
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers – Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
One in eight women will be diagnosed with breast cancer during 
Via Benzinga
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients  
Via Benzinga
Qualcomm-Apple's Chip Supply Agreement, Alleged Report About AstraZeneca CEO Sir Pascal Soriot's Intention To Step Down, Apple & Google Face Off in Antitrust Showdown: Today's Top Stories
Benzinga Qualcomm Announces Chip Supply Agreement With Apple 
Via Benzinga
What's Going On With AstraZeneca Stock Today?
Shares in European pharmaceutical giant AstraZeneca Plc (NASDAQ: AZN) are down amid speculations swirling around the potential departure of AstraZeneca's Chief Executive, Pascal Soriot. 
Via Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 phase 1b tria 
Via Benzinga
4 Top-Tier Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Deals can still be found with the Nasdaq Composite roughly 14% below its record-closing high. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Johnson & Johnson Cancer Drug Rybrevant Shows Improvement In Broader Lung Cancer Population
Janssen, a unit of Johnson & Johnson (NYSE: JNJ),  
Via Benzinga
FDA Seeks Further Safeguards for AstraZeneca's Ultomiris Therapy, But Efficacy Not in Question
The FDA has issued a complete response letter (CRL) regarding AstraZeneca Plc's (NASDAQ: 
Via Benzinga
Exposures Product Safety
3 Forever Stocks to Buy With $100
With $100 or less, you can buy at least one share of one of these top stocks. 
Via The Motley Fool
Facebook News To Shut Down In Europe, Warner Bros. Discovery Revises Outlook As Strike Bites, Manchester United No Longer Up For Sale: Today's Top Stories
Benzinga Why Facebook News is Shutting Down in Europe: What It Means for Users? 
Via Benzinga
Legal Twist In Drug Price Negotiation: Federal Judge Quits Case Amid Allegations Of Stock Ownership
On Friday, Judge Thomas Rose, serving in the U.S. 
Via Benzinga
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs? 
Via The Motley Fool
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?
The genetic test maker is rapidly increasing test volumes. 
Via The Motley Fool
Biden Administration Vs. Big Pharma: What the Legal Showdown Means for Your Wallet
The Biden administration's move to lower drug prices has prompted a flurry of legal challenges. 
Via Benzinga
Ambrx Biopharma Has Surged 483% This Year. But It Could Just Be Getting Started.
The company has another update on its prostate cancer program that could further prod shares. 
Via Investor's Business Daily
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations. 
Via The Motley Fool
Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle
The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.